サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：保因者スクリーニング：世界市場
市場調査レポート
商品コード
1193770

保因者スクリーニング：世界市場

Carrier Screening
出版日: | 発行: Global Industry Analysts, Inc. | ページ情報: 英文 173 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.76円
保因者スクリーニング：世界市場
出版日: 2023年01月01日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 173 Pages
納期: 即日から翌営業日
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

世界の保因者スクリーニングの市場規模は、COVID-19以降のビジネス環境の変化を受けて、2022年に24億米ドル、2030年には78億米ドルに達し、2022年から2030年にかけて15.8%のCAGRで成長する、と予測されます。

特に、分子スクリーニング検査は17.6%のCAGRで成長し、分析期間終了時には55億米ドルの規模に達すると予測されます。また、生化学スクリーニング検査の分野でも、COVID-19以降の回復を考慮して、今後8年間のCAGRは12.3%に再調整されています。

当レポートでは、世界の保因者スクリーニングの市場について分析し、市場の最新情勢や主な市場促進・抑制要因、全体的な市場規模の動向見通し、種類別・地域別の詳細動向、企業別の市場シェア構造、主要企業のプロファイルなどを調査しております。

分析対象企業の一例 (全42社)

  • 23andMe, Inc.
  • Abbott Laboratories
  • AutoGenomics, Inc.
  • F. Hoffmann-La Roche AG
  • Illumina, Inc.
  • Luminex Corporation
  • Myriad Genetics, Inc.
  • Sequenom, Inc.
  • Thermo Fisher Scientific, Inc.

目次

第1章 分析手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の展望

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • 他の欧州諸国
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • 他のアジア太平洋諸国
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • 他のラテンアメリカ諸国
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • 他の中東諸国
  • アフリカ

第4章 競合

目次
Product Code: MCP10911

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Carrier Screening Market to Reach $7.8 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Carrier Screening estimated at US$2.4 Billion in the year 2022, is projected to reach a revised size of US$7.8 Billion by 2030, growing at aCAGR of 15.8% over the period 2022-2030. Molecular Screening Test, one of the segments analyzed in the report, is projected to record 17.6% CAGR and reach US$5.5 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Biochemical Screening Test segment is readjusted to a revised 12.3% CAGR for the next 8-year period.

The U.S. Market is Estimated at $656.9 Million, While China is Forecast to Grow at 21.5% CAGR

The Carrier Screening market in the U.S. is estimated at US$656.9 Million in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.9 Billion by the year 2030 trailing a CAGR of 21.5% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 11.4% and 13.6% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 12.5% CAGR.

Select Competitors (Total 42 Featured):

  • 23andMe, Inc.
  • Abbott Laboratories
  • AutoGenomics, Inc.
  • F. Hoffmann-La Roche AG
  • Illumina, Inc.
  • Luminex Corporation
  • Myriad Genetics, Inc.
  • Sequenom, Inc.
  • Thermo Fisher Scientific, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Carrier Screening - Global Key Competitors Percentage Market Share in 2022 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Carrier Screening by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Carrier Screening by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 3: World 16-Year Perspective for Carrier Screening by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2023 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Molecular Screening Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Molecular Screening Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 6: World 16-Year Perspective for Molecular Screening Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Biochemical Screening Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Biochemical Screening Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 9: World 16-Year Perspective for Biochemical Screening Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Cystic Fibrosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Cystic Fibrosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 12: World 16-Year Perspective for Cystic Fibrosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Tay-Sachs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Tay-Sachs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 15: World 16-Year Perspective for Tay-Sachs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Gaucher Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Gaucher Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 18: World 16-Year Perspective for Gaucher Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Sickle Cell Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Sickle Cell Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 21: World 16-Year Perspective for Sickle Cell Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Spinal Muscular Atrophy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Spinal Muscular Atrophy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 24: World 16-Year Perspective for Spinal Muscular Atrophy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for Genetic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 26: World Historic Review for Genetic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 27: World 16-Year Perspective for Genetic Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 29: World Historic Review for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 30: World 16-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 31: World Carrier Screening Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Carrier Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2023 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2023 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2023 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2023 & 2030
  • JAPAN
    • Carrier Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2023 & 2030
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 49: Japan 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2023 & 2030
  • CHINA
    • Carrier Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • TABLE 50: China Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 52: China 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2023 & 2030
    • TABLE 53: China Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 55: China 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2023 & 2030
  • EUROPE
    • Carrier Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Carrier Screening by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Carrier Screening by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Carrier Screening by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2023 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2023 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 64: Europe 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2023 & 2030
  • FRANCE
    • Carrier Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
    • TABLE 65: France Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 67: France 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2023 & 2030
    • TABLE 68: France Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 69: France Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 70: France 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2023 & 2030
  • GERMANY
    • Carrier Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 73: Germany 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2023 & 2030
    • TABLE 74: Germany Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 75: Germany Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 76: Germany 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2023 & 2030
  • ITALY
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 79: Italy 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2023 & 2030
    • TABLE 80: Italy Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 81: Italy Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 82: Italy 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2023 & 2030
  • UNITED KINGDOM
    • Carrier Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
    • TABLE 83: UK Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 85: UK 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2023 & 2030
    • TABLE 86: UK Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 87: UK Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 88: UK 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2023 & 2030
  • SPAIN
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 91: Spain 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2023 & 2030
    • TABLE 92: Spain Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 93: Spain Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 94: Spain 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2023 & 2030
  • RUSSIA
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 97: Russia 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2023 & 2030
    • TABLE 98: Russia Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 99: Russia Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 100: Russia 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2023 & 2030
  • REST OF EUROPE
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 103: Rest of Europe 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2023 & 2030
    • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 105: Rest of Europe Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 106: Rest of Europe 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2023 & 2030
  • ASIA-PACIFIC
    • Carrier Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Carrier Screening by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Carrier Screening by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Carrier Screening by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2023 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 112: Asia-Pacific 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2023 & 2030
    • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 114: Asia-Pacific Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 115: Asia-Pacific 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2023 & 2030
  • AUSTRALIA
    • Carrier Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 118: Australia 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2023 & 2030
    • TABLE 119: Australia Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 120: Australia Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 121: Australia 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2023 & 2030
  • INDIA
    • Carrier Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
    • TABLE 122: India Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 124: India 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2023 & 2030
    • TABLE 125: India Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 126: India Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 127: India 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2023 & 2030
  • SOUTH KOREA
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 130: South Korea 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2023 & 2030
    • TABLE 131: South Korea Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 132: South Korea Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 133: South Korea 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2023 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2023 & 2030
    • TABLE 137: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 138: Rest of Asia-Pacific Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 139: Rest of Asia-Pacific 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2023 & 2030
  • LATIN AMERICA
    • Carrier Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Carrier Screening by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Carrier Screening by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Carrier Screening by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2023 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 145: Latin America 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2023 & 2030
    • TABLE 146: Latin America Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 147: Latin America Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 148: Latin America 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2023 & 2030
  • ARGENTINA
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 151: Argentina 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2023 & 2030
    • TABLE 152: Argentina Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 153: Argentina Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 154: Argentina 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2023 & 2030
  • BRAZIL
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 157: Brazil 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2023 & 2030
    • TABLE 158: Brazil Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 159: Brazil Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 160: Brazil 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2023 & 2030
  • MEXICO
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 163: Mexico 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2023 & 2030
    • TABLE 164: Mexico Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 165: Mexico Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 166: Mexico 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2023 & 2030
  • REST OF LATIN AMERICA
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 169: Rest of Latin America 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2023 & 2030
    • TABLE 170: Rest of Latin America Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 171: Rest of Latin America Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 172: Rest of Latin America 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2023 & 2030
  • MIDDLE EAST
    • Carrier Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Carrier Screening by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Carrier Screening by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Carrier Screening by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2023 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 178: Middle East 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2023 & 2030
    • TABLE 179: Middle East Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 180: Middle East Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 181: Middle East 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2023 & 2030
  • IRAN
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 184: Iran 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2023 & 2030
    • TABLE 185: Iran Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 186: Iran Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 187: Iran 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2023 & 2030
  • ISRAEL
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 190: Israel 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2023 & 2030
    • TABLE 191: Israel Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 192: Israel Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 193: Israel 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2023 & 2030
  • SAUDI ARABIA
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 196: Saudi Arabia 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2023 & 2030
    • TABLE 197: Saudi Arabia Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 198: Saudi Arabia Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 199: Saudi Arabia 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2023 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 202: UAE 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2023 & 2030
    • TABLE 203: UAE Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 204: UAE Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 205: UAE 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2023 & 2030
  • REST OF MIDDLE EAST
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 208: Rest of Middle East 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2023 & 2030
    • TABLE 209: Rest of Middle East Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 210: Rest of Middle East Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 211: Rest of Middle East 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2023 & 2030
  • AFRICA
    • Carrier Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Carrier Screening by Test Type - Molecular Screening Test and Biochemical Screening Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 214: Africa 16-Year Perspective for Carrier Screening by Test Type - Percentage Breakdown of Value Sales for Molecular Screening Test and Biochemical Screening Test for the Years 2014, 2023 & 2030
    • TABLE 215: Africa Recent Past, Current & Future Analysis for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 216: Africa Historic Review for Carrier Screening by Disease Type - Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 217: Africa 16-Year Perspective for Carrier Screening by Disease Type - Percentage Breakdown of Value Sales for Genetic Disorders, Cystic Fibrosis, Spinal Muscular Atrophy, Gaucher Disease, Tay-Sachs, Sickle Cell Disease and Other Disease Types for the Years 2014, 2023 & 2030

IV. COMPETITION